Literature DB >> 24930324

[Influence of tapentadol retard on functional parameters in patients with severe chronic pain--is there a benefit in daily life?].

M Strohmeier, S Waldmann-Rex, K Schwenke.   

Abstract

BACKGROUND: A patient-orientated therapy management for patients with severe chronic pain includes effective analgesia, improvement of health related quality of life and improvement of functionality. PATIENTS AND
METHOD: In this prospective, non-interventional trial in 630 patients with severe chronic pain mostly due to chronic low back pain or gonarthrosis, treatment with tapentadol retard was evaluated with respect to its effects on analgesia, functionality and quality of life. Collected data included pain intensity, painDETECT,SF-12, FFbH-R and FFbH-OA.
RESULTS: Mean pain intensity decreased significantly (NRS-3: -3.2 points, p < or = 0.001) and in 47.9% of the patients the mean pain intensity was reduced by at least 50%. Health-related quality of life and functionality improved significantly. Tolerability was good. The known tolerability profile of tapentadol retard could be confirmed.
CONCLUSION: In this study in real-life-setting tapentadol was effective in terms of analgesic effect but also in terms of improvementof health-related quality of life and functionality, leading to a benefit for the patient in daily life.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24930324     DOI: 10.1007/s15006-013-1056-0

Source DB:  PubMed          Journal:  MMW Fortschr Med        ISSN: 1438-3276


  2 in total

1.  Tapentadol prolonged release for severe chronic cancer-related pain: effectiveness, tolerability, and influence on quality of life of the patients.

Authors:  Artur Schikowski; Doris Krings; Karla Schwenke
Journal:  J Pain Res       Date:  2014-12-22       Impact factor: 3.133

2.  Tapentadol Prolonged Release for Severe Chronic Osteoarthritis Pain in the Elderly-A Subgroup Analysis of Routine Clinical Practice Data.

Authors:  Andreas Schwittay; Melanie Sohns; Birgit Heckes; Christian Elling
Journal:  Pain Res Manag       Date:  2020-04-14       Impact factor: 3.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.